Friday, 01 July 2022 12:46

Anticoagulation news items. Week commencing 27th June 2022

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial

European Heart Journal
Analysis found rivaroxaban + aspirin vs aspirin produces similar effects for major adverse cardiovascular events, major bleeding and net clinical outcome but is associated with higher rates of intracranial haemorrhage in Asians.


2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

The Lancet Oncology
Key recommendations include low-molecular-weight heparins for initial (first 10 days) & maintenance treatment of cancer-associated thrombosis or DOACs in patients who are not at high risk of GI or genitourinary bleeding, providing no strong drug interactions or absorption issues.


Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

The Lancet
RCT (n=1600) suggests single bolus of IV tenecteplase (0.25 mg/kg) is a reasonable alternative to alteplase bolus followed by infusion (36·9% vs. 34·8%, respectively, had modified Rankin Scale score of 0–1 at 90–120 days meeting prespecified non-inferiority threshold).


Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

The Lancet Haematology
RCT (n=472) found thromboprophylaxis with enoxaparin 40 mg once daily for 14 days does not reduce early hospitalisations & deaths among outpatients with symptomatic COVID-19 versus standard of care (no thromboprophylaxis) and was terminated early due to futility of the treatment.


Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

The Lancet Haematology
Study terminated early due to slow enrolment & lower-than-expected event rate (n=219) found prophylaxis with low-molecular-weight heparin had no benefit for at-risk outpatients with COVID-19 vs. standard-of-care (all cause mortality & hospitalisation at 21 days =11% each group).


Prescribing direct-acting oral anticoagulants – mind the evidence gap

British Journal of Clinical Pharmacology
Review notes prescribers may not be aware of the under representation of patient populations commonly encountered in clinical practice within the trials supporting approval of DOACs and highlights the gaps in licensing evidence using 4 clinical vignettes.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: